Vessel Preparation for Tibial Interventions: Why “Just PTA” Is Rarely Enough
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.
Advanced Interventional and Vascular Services, New Jersey
During a Wednesday afternoon session at ISET 2026, John H. Rundback, MD, FAHA, FSVM, FSIR, from Advanced Interventional and Vascular Services in New Jersey, challenged the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia (CLTI). He walked through the evolving science and real-world complexity behind infrapopliteal disease, making the case that vessel preparation is no longer optional but foundational.
Drawing from randomized trials, cohort studies, and large retrospective analyses, the presentation highlighted just how heterogeneous tibial disease truly is. High rates of calcification, long lesion length, chronic total occlusions, and the frequent presence of acute or chronic thrombus all limit the durability of “just PTA.” Dr Rundback emphasized that more than 70% of severely stenotic infrapopliteal arteries demonstrate thrombotic material, a finding that has major implications for embolization risk, dissections, and drug delivery if vessel preparation is overlooked.
Dr Rundback reviewed contemporary vessel preparation strategies, ranging from high-pressure noncompliant balloons and specialty scoring or serration balloons to atherectomy and intravascular lithotripsy, and positioned each tool within a practical, lesion-specific framework. Data supporting high-pressure noncompliant balloon angioplasty showed favorable safety, technical success, and limb-salvage outcomes even in long, heavily calcified tibial lesions, while emerging technologies such as serration balloons demonstrated low dissection rates and minimal need for bailout stenting in early studies. Atherectomy was discussed with attention paid to both its potential advantages in long or calcified lesions and the importance of careful patient and lesion selection given mixed reintervention data.
Rather than advocating a single “best” device, Dr Rundback underscored the importance of tailoring strategy to lesion length, calcification severity, thrombus burden, and procedural goals, especially when definitive therapies such as drug-eluting stents, bioresorbable scaffolds, or other adjuncts are planned.
In conclusion, Dr Rundback said that in today’s CLTI population, vessel preparation is not a luxury or a bailout maneuver. Instead, it is a deliberate, evidence-informed step that can meaningfully affect procedural safety and long-term outcomes.
